Hepatitis aguda grave de origen desconocido / Severe acute hepatitis of unknown origin

Resumen A inicios de 2022, en Reino Unido, y posteriormente en varios países europeos, se informó sobre un grupo de pacientes pediátricos que desarrollaron hepatitis aguda de origen desconocido hasta ahora. Los datos clínicos consisten en náusea, vómito, ictericia y falla hepática; algunos pacientes necesitan trasplante hepático. La población afectada es menor a los 10 años. El agente etiológico probable es el adenovirus genotipo F41 y se han descartado factores tóxicos, así como la relación con COVID-19. Existen varias teorías para explicar este fenómeno, las cuales se están investigando.

Abstract At the beginning of 2022, in the United Kingdom, and later in several European countries, a group of pediatric patients who developed acute hepatitis of so far unknown origin was reported. Clinical data include nausea, vomiting, jaundice, and liver failure; some patients require liver transplantation. The affected population is younger than 10 years of age. The probable etiological agent is adenovirus genotype F41, and toxic factors have been ruled out, as well as a relationship with COVID-19. There are several theories to explain this phenomenon, which are being investigated.

Inibidores de bomba protônica aumentam o risco geral de desenvolver infecções bacterianas em pacientes com cirrose / Proton pump inhibitors increase the overall risk of developing bacterial infections in patients with cirrhosis

ABSTRACT BACKGROUND: Acid suppression has been associated with adverse events; such as, enteric infections. Proton pump inhibitors (PPI) are frequently prescribed in patients with cirrhosis, but is unclear if PPI are associated with the development of bacterial infections in these patients. OBJECTIVE: To assess the impact of PPI intake on the development of bacterial, viral and fungal infections in patients with cirrhosis. METHODS: An observational, retrospective, historic cohort study. The exposed cohort included patients with cirrhosis with chronic use of PPI. The non-exposed cohort had not been using PPI. The follow-up period was 3 years, searching in the medical records for any events of bacterial infection confirmed by bacteriological culture. RESULTS: One hundred and thirteen patients met the selection criteria, 44 (39%) had chronic use of PPI; of them, 28 (63.6%) patients had not a clear clinical indication to justify the prescription of PPI. Twenty four (21.2%) patients developed bacterial infections during the follow-up period. In the univariate analysis, decompensated cirrhosis (Child B/C), presence of ascites, history of variceal bleeding, and chronic consumption of PPI were risk factors related to the development of infections. But, in the adjusted multivariate analysis only the chronic use of PPI was associated with development of infections (RR=3.6; 95% CI=1.1-12.3; P=0.04). CONCLUSION: There is an over-prescription of PPI without a justified clinical indication. The long-term consumption of PPI in patients with cirrhosis is associated with the development of bacterial infections; therefore these drugs must be carefully prescribed in this specific population.

RESUMO CONTEXTO: A supressão de ácido tem sido associada a efeitos adversos, tais como infecções entéricas. Inibidores da bomba protônica são frequentemente prescritos em pacientes com cirrose, mas não está claro se o inibidor de bomba de próton (IBP) está associado ao desenvolvimento de infecções bacterianas nesses pacientes. OBJETIVO: Avaliar o impacto da ingestão de IBP no desenvolvimento de infecção bacteriana, viral e fúngica em pacientes com cirrose. MÉTODOS: Foi realizado estudo de coorte observacional, retrospectivo, histórico. A coorte exposta incluiu pacientes com cirrose e com uso crônico de IBP. A coorte de não expostos não estava usando IBP. O período de seguimento foi de 3 anos, procurando-se nos registros médicos qualquer evento de infecção bacteriana, confirmada pela cultura bacteriológica. RESULTADOS: Cento e treze pacientes preencheram os critérios de seleção, 44 (39%) pacientes faziam uso crônico de IBP; deles, 28 (63,6%) não tinham uma indicação clínica clara para justificar a prescrição de IBP. Vinte e quatro (21,2%) pacientes desenvolveram infecções bacterianas durante o período de seguimento. Na análise univariada, cirrose descompensada (Child B/C), presença de ascite, história de hemorragia varicosa e consumo crônico de IBP foram fatores de risco relacionados ao desenvolvimento de infecções. Porém, na análise multivariada ajustada, somente o uso crônico de IBP foi associado ao desenvolvimento de infecções (RR=3,6; 95% CI = 1.1-12.3; P=0,04). CONCLUSÃO: Há uma prescrição excessiva de PPI sem uma indicação clínica justificada. O consumo de longo prazo do IBP em pacientes com cirrose é associado ao desenvolvimento de infecções bacterianas. Portanto, essas drogas devem ser cuidadosamente prescritas nesta população específica.

Feocromocitoma. Presentación de un caso / Pheochromocytoma. A case report

El feocromocitoma es un tumor de la médula adrenal de las células cromafines, derivadas de la cresta neural secretoras de catecolaminas (adrenalina, noradrenalina y menos frecuente dopamina). Se presenta un caso de una mujer joven en el servicio de urgencias del Hospital General Docente Abel Santamaría Cuadrado, con un dolor en el hemiabdomen derecho de varios días de evolución y con cifras de tensión arterial elevada. Se realizó un examen físico exhaustivo, estudios de ecografía abdominal y TAC. Se constató una masa suprarrenal derecha de morfología ovalada y de bordes bien delimitados, que recuerda la imagen de un feocromocitoma; se corroboró por anatomía patológica y confirmó el diagnóstico con características de malignidad. La paciente evolucionó desfavorablemente en el post-operatorio y presentó crisis hipertensivas provocándole la muerte.

Pheochromocytoma is a tumor of the adrenal medulla in chromaffin cells derived from secretory neural crest of catecholamines (adrenaline, noradrenaline and less frequent dopamine). A case of a young woman attended to the Emergency Room at “Abel Santamaria Cuadrado” hospital is analyzed, the patient complained of a pain in the right hemi-abdomen, of some days of evolution and hypertension. An exhaustive physical examination, abdominal sonography and Axial Computerize Tomography were performed. A right adrenal mass of oval morphology and well-delimited borders, similar to the image of a Pheochromocytoma; pathologic anatomy confirmed the diagnosis with malignant characteristics. The patient showed a favourable post-operative progress but presented a hypertensive crisis which provoked the death.

Utility of the Dipstick Micraltest II TM in the screening of microalbuminuria of diabetes mellitus type 2 and essential hypertension / Utilidad de la tira reactiva Micraltest II TMen el escrutinio de microalbuminuria en diabetes mellitus tipo 2 e hipertensión esencial

Background. In Mexico, diabetes mellitus type 2 and hypertension are leading causes of end-stage renal disease. Diagnosis of early renal damage with detection of microalbuminuria (microAlbU) is fundamental for treatment and prevention, and so avoiding the catastrophes of renal failure. For screening purposes, several simplified tests, including dipstick methods, fulfill the accuracy requirements for microAlbU detection compared with gold standards; however, no study has established the reliability of such tests in our setting. Aim. To evaluate the utility of micraltest II TM as a screening test for microAlbU compared with nephelometry in patients with diabetes mellitus type 2 and non-diabetic patients with essential hypertension. Patients and methods. Patients with diabetes mellitus type 2 as well as patients with essential hypertension of any age, sex and time of evolution, attending to three primary health-care units (UMF No. 3, 92 and 93, Guadalajara, Jalisco) were included. Patients with transitory albuminuria, secondary hypertension and serum creatinine > 2 mg/dL were excluded. Micraltest II TM was performed in the first morning urine sample, and nephelometry was performed in a 24-h urine collection. Diagnostic accuracy of the dipstick test was then determined. Results. 245 patients were studied: 71 (29%) were diabetics without hypertension, 95 (39%) were diabetics with hypertension, and 79 (32%) had only essential hypertension. In diabetic patients, micraltest II TM sensitivity was 83%, specificity 96%, and positive and negative predictive values were 95% and 88%, respectively. Correlation between nephelometry and micraltest II TM results was 0.81 (p < 0.001). The best cut-off point for microAlbU was 30.5 mg/L, and area under the curve (± SEM) was 0.91 ± 0.03 (confidence interval 95%: 0.85-0.96). In non-diabetic patients with essential hypertension, micraltest II TM sensitivity was 75%, specificity 95%, and positive and negative predictive values were 43% and 99%, respectively. Correlation between nephelometry and micraltest II TM results was 0.43 (p < 0.001). The best cut-off point for microAlbU was 28.2 mg/L, and area under the curve was 0.85 ± 0.13 (0.60-1.10). Conclusion. Micraltest II TM dispstick is a rapid, valid and reliable method for albuminuria screening in patients with diabetes mellitus type 2 and in those non-diabetic patients with essential hypertension in our setting.

Antecedentes. En México, la diabetes mellitus tipo 2 y la hipertensión son las principales causas de insuficiencia renal crónica terminal. El diagnóstico temprano con detección de microalbuminuria (microAlbU) es fundamental para el tratamiento y prevención, y así evitar las catástrofes de la falla renal. Con el fin de tamizaje, varias pruebas simples, incluyendo las tiras reactivas, cumplen con los requerimientos de exactitud para detección de microAlbU comparados con esténdares de oro; sin embargo, ningún estudio ha establecido la confiabilidad de dichos métodos en nuestro medio. Objetivo. Evaluar la utilidad del micraltest II TM como prueba de tamizaje para microAlbU comparada con nefelometría en pacientes con diabetes mellitus tipo 2 y pacientes no diabáticos con hipertensión arterial esencial. Pacientes y métodos. Se incluyeron pacientes con diabetes mellitus tipo 2, así como pacientes con hipertensión arterial esencial de cualquiera de los dos sexos, sexo y tiempo de evolución que atendían a tres unidades de Medicina Familiar (UMF No. 3, 92 y 93, Guadalajara, Jalisco). Se excluyeron pacientes con albuminuria transitoria, hipertensión secundaria y creatinina sárica > 2 mg/dL. El micraltest II TM se realizó en la primera muestra matutina de orina, y la nefelometría en recolecciones de orina de 24 horas. La exactitud diagnóstica de la tira reactiva fue luego determinada. Resultados. Doscientos cuarenta y cinco pacientes fueron estudiados: 71 (29%) eran diabáticos sin hipertensión, 95 (39%) eran diabáticos con hipertensión, y 79 (32%) tenían sólo hipertensión arterial esencial. En los pacientes diabáticos, el micraltest II TM tuvo una sensibilidad de 83%, especificidad de 96%, y valores predictivos positivo y negativo de 95% y 88%, respectivamente. La correlación entre la nefelometría y el micraltest II TM fue 0.81 (p < 0.001). El mejor punto de corte para la detección de microAlbU fue 30.5 mg/L, y el área bajo la curva (± EE) fue 0.91 ± 0.03 (intervalo de confianza 95%: 0.85-0.96). En los pacientes no diabáticos con hipertensión esencial, el micraltest II TM tuvo una sensibilidad de 75%, especificidad de 95%, y valores predictivos positivo y negativo de 43 y 99%, respectivamente. La correlación entre los resultados de nefelometría y micraltest II TM fue 0.43 (p < 0.001). El mejor punto de corte para microAlbU fue 28.2 mg/L, y el área bajo la curva fue 0.85 ± 0.13 (intervalo de confianza 95%:0.60-1.10). Conclusión. La tira reactiva micraltest II TM es un método rápido, válido y confiable para el tamizaje de albuminuria en pacientes con diabetes mellitus tipo 2 y pacientes no diabáticos con hipertensión arterial esencial en nuestro medio.